
H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on IMUX stock, giving a Buy rating on November 9. Matthew Caufield gave his Buy rating based on several factors,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IMUX | Immunic | 7.39 | 0.38 | 5.43% |
| Name | Price | % Change | |
|---|---|---|---|
| $7.39 | +5.43% |

H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on IMUX stock, giving a Buy rating on November 9. Matthew Caufield gave his Buy rating based on several factors,

Stock futures are higher as investors weigh Nvidia’s leadership turmoil, persistent inflation concerns and the latest wholesale-price data. Nvidia shares are rebounding more than 2% in premarket trading after Thursday’s

“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis in December, we believe Immunic (IMUX) is entering one of the most important periods

Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Immunic and keeping the price target at $22.00. Matthew Caufield’s rating is based on several factors, including the substantial

Immunic ( ($IMUX) ) has issued an announcement. Immunic, a pharmaceutical developer focused on product candidates for targeted diseases including progressive multiple sclerosis, hosted a Progressive Multiple Sclerosis Research and

Immunic, Inc. (IMUX) is scheduled to report 3rd quarter earnings on 10/29/2026. Regarding Q3 estimates, Wall Street analysts expect Immunic, Inc. to post earnings of -$0.94 per share. Last quarter,

Cantor Fitzgerald initiated coverage of Immunic (IMUX) with an Overweight rating. Immunic offers attractive risk/reward ahead of anticipated December 2026 Phase 3 RMS readouts for vidofludimus calcium, with a roughly

Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Immunic (IMUX) with an Overweight rating. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Immunic (IMUX) announced the appointment of Jaa Roberson as chief people officer, or CPO, effective immediately. Roberson will report directly to CEO Erik Lundgren and will serve as a member

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunic today and set a price target of $56.00. Sam Slutsky has given his Buy rating due to a combination
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 17, 2026 | ||||
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| buy | Initiated | Oct 23, 2026 | ||||
| buy | Reiterated | Sep 11, 2026 | ||||
| buy | Reiterated | Sep 10, 2026 | ||||
| buy | Reiterated | Sep 2, 2026 | ||||
| buy | Reiterated | Sep 1, 2026 | ||||
| buy | Reiterated | Aug 11, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 25, 2027TBA | $119.42M | $-0.82 | $0.00 | 0.02 | -1.68 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.